Trey Sunderland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Trey Sunderland has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Karen T. Putnam
Litwin-Zucker Research Center, North Shore-LIJ Health System, Great Neck, New York
2 shared publicationsRobert M. Cohen
Department of Psychiatry, Cedars-Sinai Medical Center, Los Angeles, California
2 shared publicationsDavid Friedman
1 shared publicationDeepa Bhupali
1 shared publicationGary Linker
1 shared publicationGyorgy Csako
1 shared publication
Latest Publications
- 1 September 2006
- Published by SAGE Publications in Journal of Geriatric Psychiatry and Neurology
- Vol. 19 (3) , 172-179
Biomarkers in the Diagnosis of Alzheimer’s Disease: Are We Ready?
Although clinical manifestations of cognitive dysfunction and impairments of activities of daily living are the current standard measures for the diagnosis of Alzheimer’s disease, biomarkers are receiving increasing attention in research centers as possible early diagnostic measures or as surrogate measures of the ongoing pathology. In preparation for the upcoming development of the Diagnostic and Statistical Manual of Mental Disorders (5th ed; DSM-V) nosology, the American Psychiatric Association has sponsored an effort to reassess the current approaches to diagnosis in dementia in general and Alzheimer’s disease in particular. This article focuses on the potential use of biomarkers in the diagnosis of Alzheimer’s disease, in the monitoring of mild cognitive impairment, and as possible prognostic markers in normal controls at risk for dementia. Most advanced information is available with the biomarkers found in the cerebrospinal fluid, but there are many other potential biomarkers using blood, brain imaging, or a combination. The current biomarker approaches to diagnosis are reviewed along with a special emphasis on near-term recommendations and further research directions. (J Geriatr Psychiatry Neurol 2006;19:172-179)
- 1 September 2006
- Published by SAGE Publications in Journal of Geriatric Psychiatry and Neurology
- Vol. 19 (3) , 172-179
Biomarkers in the Diagnosis of Alzheimer’s Disease: Are We Ready?
Although clinical manifestations of cognitive dysfunction and impairments of activities of daily living are the current standard measures for the diagnosis of Alzheimer’s disease, biomarkers are receiving increasing attention in research centers as possible early diagnostic measures or as surrogate measures of the ongoing pathology. In preparation for the upcoming development of the Diagnostic and Statistical Manual of Mental Disorders (5th ed; DSM-V) nosology, the American Psychiatric Association has sponsored an effort to reassess the current approaches to diagnosis in dementia in general and Alzheimer’s disease in particular. This article focuses on the potential use of biomarkers in the diagnosis of Alzheimer’s disease, in the monitoring of mild cognitive impairment, and as possible prognostic markers in normal controls at risk for dementia. Most advanced information is available with the biomarkers found in the cerebrospinal fluid, but there are many other potential biomarkers using blood, brain imaging, or a combination. The current biomarker approaches to diagnosis are reviewed along with a special emphasis on near-term recommendations and further research directions. (J Geriatr Psychiatry Neurol 2006;19:172-179)
- 15 August 2005
- Published by Elsevier in Biological Psychiatry
- Vol. 58 (4) , 272-276
The Use of Biomarkers in the Elderly: Current and Future Challenges
- 15 August 2005
- Published by Elsevier in Biological Psychiatry
- Vol. 58 (4) , 272-276
The Use of Biomarkers in the Elderly: Current and Future Challenges
- 1 August 2005
- Published by Elsevier in Biological Psychiatry
- Vol. 58 (4) , 263-264
Geriatric Psychiatry: Coming of Age in America
- 1 August 2005
- Published by Elsevier in Biological Psychiatry
- Vol. 58 (4) , 263-264
Geriatric Psychiatry: Coming of Age in America
- 1 November 2004
- Published by Elsevier in Biological Psychiatry
- Vol. 56 (9) , 670-676
Cerebrospinal fluid β-amyloid1–42 and tau in control subjects at risk for Alzheimer’s disease: The effect of APOE ε4 allele
- 1 November 2004
- Published by Elsevier in Biological Psychiatry
- Vol. 56 (9) , 670-676
Cerebrospinal fluid β-amyloid1–42 and tau in control subjects at risk for Alzheimer’s disease: The effect of APOE ε4 allele
- 1 January 2000
- Published by American Psychological Association (APA) in Neuropsychology
- Vol. 14 (2) , 288-298
Acetylcholine affects the spatial scale of attention: Evidence from Alzheimer's disease.
Location precues were used to manipulate the spatial scale of attention in visual search for a target in an array of letters in patients with dementia of the Alzheimer type (DAT) and in age-matched older controls. Cue size varied in the amount of spatial precision conferred. Scopolamine, a muscarinic antagonist, decreased overall arousal and broadened spatial attention after a precise precue (small and valid) to target location for DAT patients but not for controls, suggesting a selective effect for attentional impairment induced by cholinergic blockade. In contrast, physostigmine, a cholinesterase inhibitor, did not alter the distribution of spatial attention relative to no-drug baseline testing for patients. Results support a differential role for cholinergic mechanisms in the modulation of the spatial scale of visual attention.
- 1 January 2000
- Published by American Psychological Association (APA) in Neuropsychology
- Vol. 14 (2) , 288-298
Acetylcholine affects the spatial scale of attention: Evidence from Alzheimer's disease.
Location precues were used to manipulate the spatial scale of attention in visual search for a target in an array of letters in patients with dementia of the Alzheimer type (DAT) and in age-matched older controls. Cue size varied in the amount of spatial precision conferred. Scopolamine, a muscarinic antagonist, decreased overall arousal and broadened spatial attention after a precise precue (small and valid) to target location for DAT patients but not for controls, suggesting a selective effect for attentional impairment induced by cholinergic blockade. In contrast, physostigmine, a cholinesterase inhibitor, did not alter the distribution of spatial attention relative to no-drug baseline testing for patients. Results support a differential role for cholinergic mechanisms in the modulation of the spatial scale of visual attention.